Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Residual Disease in Spondyloarthritis: What's Being Missed by DMARDs?

(MedPage Today) -- In spondyloarthritis (SpA), the wealth of biologic and disease-modifying anti-rheumatic drug (DMARD) options still leaves some patients unsatisfied with their treatment outcomes, most likely due to residual disease. This year...

Residual Disease in Spondyloarthritis: What's Being Missed by DMARDs?

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 2 November →